Which has higher earnings and valuation, IBRX or ONC?

BeOne Medicines has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 65.64 -$351.40M -$0.85 N/A BeOne Medicines $5.34B 5.43 $286.93M $4.47 59.17

Does the media refer more to IBRX or ONC?

In the previous week, BeOne Medicines had 11 more articles in the media than ImmunityBio. MarketBeat recorded 14 mentions for BeOne Medicines and 3 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.51 beat BeOne Medicines' score of 0.17 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BNTX or IBRX more profitable?

BioNTech has a net margin of -44.39% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% ImmunityBio -606.15% N/A -59.53%

Does the media favor BNTX or IBRX?

In the previous week, BioNTech had 2 more articles in the media than ImmunityBio. MarketBeat recorded 5 mentions for BioNTech and 3 mentions for ImmunityBio. BioNTech's average media sentiment score of 0.63 beat ImmunityBio's score of 0.51 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ROIV or IBRX?

In the previous week, Roivant Sciences had 8 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Roivant Sciences and 3 mentions for ImmunityBio. Roivant Sciences' average media sentiment score of 1.56 beat ImmunityBio's score of 0.51 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, IBRX or INSM?

ImmunityBio has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 65.64 -$351.40M -$0.85 N/A Insmed $606.42M 34.97 -$1.28B -$5.75 N/A

Is IBRX or INSM more profitable?

Insmed has a net margin of -144.44% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Insmed -144.44% -130.11% -51.57%

Does the media refer more to IBRX or INSM?

In the previous week, Insmed had 20 more articles in the media than ImmunityBio. MarketBeat recorded 23 mentions for Insmed and 3 mentions for ImmunityBio. Insmed's average media sentiment score of 0.89 beat ImmunityBio's score of 0.51 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 16 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, IBRX or VTRS?

ImmunityBio has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 65.64 -$351.40M -$0.85 N/A Viatris $14.30B 1.34 -$3.51B -$0.26 N/A

Is IBRX or VTRS more profitable?

Viatris has a net margin of -2.04% compared to ImmunityBio's net margin of -606.15%. Viatris' return on equity of 19.04% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Viatris -2.04% 19.04% 7.62%

ImmunityBio (IBRX) Competitors

$7.10 -0.10 (-1.39%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$7.10 +0.01 (+0.07%)

As of 06/12/2026 07:59 PM Eastern

Compare

IBRX vs. ONC, BNTX, ROIV, INSM, and VTRS

Should you buy ImmunityBio stock or one of its competitors? MarketBeat compares ImmunityBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImmunityBio include BeOne Medicines (ONC), BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does ImmunityBio compare to BeOne Medicines?

ImmunityBio (NASDAQ:IBRX) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

ImmunityBio currently has a consensus target price of $14.20, indicating a potential upside of 100.00%. BeOne Medicines has a consensus target price of $390.00, indicating a potential upside of 47.46%. Given ImmunityBio's higher probable upside, research analysts clearly believe ImmunityBio is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

BeOne Medicines has a net margin of 8.94% compared to ImmunityBio's net margin of -606.15%. BeOne Medicines' return on equity of 12.06% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
BeOne Medicines	8.94%	12.06%	6.69%

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 69.5% of ImmunityBio shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, BeOne Medicines had 11 more articles in the media than ImmunityBio. MarketBeat recorded 14 mentions for BeOne Medicines and 3 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.51 beat BeOne Medicines' score of 0.17 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	65.64	-$351.40M	-$0.85	N/A
BeOne Medicines	$5.34B	5.43	$286.93M	$4.47	59.17

ImmunityBio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Summary

BeOne Medicines beats ImmunityBio on 13 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to BioNTech?

BioNTech (NASDAQ:BNTX) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

ImmunityBio has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.05	-$1.29B	-$5.88	N/A
ImmunityBio	$113.29M	65.64	-$351.40M	-$0.85	N/A

BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market.

BioNTech currently has a consensus target price of $129.56, suggesting a potential upside of 43.10%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 100.00%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

BioNTech has a net margin of -44.39% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
ImmunityBio	-606.15%	N/A	-59.53%

In the previous week, BioNTech had 2 more articles in the media than ImmunityBio. MarketBeat recorded 5 mentions for BioNTech and 3 mentions for ImmunityBio. BioNTech's average media sentiment score of 0.63 beat ImmunityBio's score of 0.51 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 69.5% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BioNTech beats ImmunityBio on 10 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Roivant Sciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market.

Roivant Sciences has higher earnings, but lower revenue than ImmunityBio. Roivant Sciences is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,615.84	-$299.77M	-$0.60	N/A
ImmunityBio	$113.29M	65.64	-$351.40M	-$0.85	N/A

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 69.5% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ImmunityBio has a net margin of -606.15% compared to Roivant Sciences' net margin of -3,629.19%. ImmunityBio's return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
ImmunityBio	-606.15%	N/A	-59.53%

Roivant Sciences presently has a consensus price target of $33.59, indicating a potential upside of 11.82%. ImmunityBio has a consensus price target of $14.20, indicating a potential upside of 100.00%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Roivant Sciences had 8 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Roivant Sciences and 3 mentions for ImmunityBio. Roivant Sciences' average media sentiment score of 1.56 beat ImmunityBio's score of 0.51 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Roivant Sciences beats ImmunityBio on 10 of the 16 factors compared between the two stocks.

How does ImmunityBio compare to Insmed?

ImmunityBio (NASDAQ:IBRX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Insmed has a net margin of -144.44% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Insmed	-144.44%	-130.11%	-51.57%

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 100.00%. Insmed has a consensus target price of $212.50, suggesting a potential upside of 117.17%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Insmed had 20 more articles in the media than ImmunityBio. MarketBeat recorded 23 mentions for Insmed and 3 mentions for ImmunityBio. Insmed's average media sentiment score of 0.89 beat ImmunityBio's score of 0.51 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	16 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

ImmunityBio has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	65.64	-$351.40M	-$0.85	N/A
Insmed	$606.42M	34.97	-$1.28B	-$5.75	N/A

8.6% of ImmunityBio shares are owned by institutional investors. 69.5% of ImmunityBio shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Insmed beats ImmunityBio on 10 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Viatris?

ImmunityBio (NASDAQ:IBRX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

In the previous week, ImmunityBio had 2 more articles in the media than Viatris. MarketBeat recorded 3 mentions for ImmunityBio and 1 mentions for Viatris. Viatris' average media sentiment score of 0.72 beat ImmunityBio's score of 0.51 indicating that Viatris is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmunityBio	Positive
Viatris	Positive

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 69.5% of ImmunityBio shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImmunityBio has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	65.64	-$351.40M	-$0.85	N/A
Viatris	$14.30B	1.34	-$3.51B	-$0.26	N/A

ImmunityBio has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Viatris has a net margin of -2.04% compared to ImmunityBio's net margin of -606.15%. Viatris' return on equity of 19.04% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Viatris	-2.04%	19.04%	7.62%

ImmunityBio currently has a consensus price target of $14.20, indicating a potential upside of 100.00%. Viatris has a consensus price target of $17.50, indicating a potential upside of 6.19%. Given ImmunityBio's stronger consensus rating and higher probable upside, research analysts clearly believe ImmunityBio is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

ImmunityBio and Viatris tied by winning 8 of the 16 factors compared between the two stocks.

Get ImmunityBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBRX vs. The Competition

Export

Metric	ImmunityBio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.54B	$3.39B	$6.75B	$12.02B
Dividend Yield	N/A	2.25%	2.66%	5.61%
P/E Ratio	-8.35	19.48	23.82	24.42
Price / Sales	65.64	304.87	510.69	109.73
Price / Cash	N/A	124.89	44.01	55.64
Price / Book	-13.92	8.32	10.66	6.79
Net Income	-$351.40M	$23.89M	$3.57B	$337.66M
7 Day Performance	2.60%	3.56%	0.87%	2.56%
1 Month Performance	-12.88%	-1.29%	0.18%	2.03%
1 Year Performance	131.27%	44.89%	25.23%	30.31%

ImmunityBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBRX ImmunityBio	3.1222 of 5 stars	$7.10 -1.4%	$14.20 +100.0%	+122.6%	$7.54B	$113.29M	N/A	590
ONC BeOne Medicines	4.1603 of 5 stars	$264.93 -1.2%	$390.00 +47.2%	-4.4%	$29.05B	$5.34B	59.24	12,000	News Coverage Insider Trade
BNTX BioNTech	4.2905 of 5 stars	$86.34 -0.2%	$129.56 +50.1%	-13.7%	$21.76B	$3.25B	N/A	7,807
ROIV Roivant Sciences	2.3036 of 5 stars	$28.78 -0.9%	$33.59 +16.7%	+161.9%	$20.69B	$8.26M	N/A	860	Positive News
INSM Insmed	3.1529 of 5 stars	$94.45 -4.6%	$212.50 +125.0%	+1.0%	$20.37B	$606.42M	N/A	1,664	Positive News Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBRX) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmunityBio (IBRX) Competitors

IBRX vs. ONC, BNTX, ROIV, INSM, and VTRS

How does ImmunityBio compare to BeOne Medicines?

Summary

How does ImmunityBio compare to BioNTech?

Summary

How does ImmunityBio compare to Roivant Sciences?

Summary

How does ImmunityBio compare to Insmed?

Summary

How does ImmunityBio compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX vs. The Competition

ImmunityBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmunityBio (IBRX) Competitors

IBRX vs. ONC, BNTX, ROIV, INSM, and VTRS

How does ImmunityBio compare to BeOne Medicines?

Do analysts recommend IBRX or ONC?

Is IBRX or ONC more profitable?

Do institutionals and insiders believe in IBRX or ONC?

Does the media refer more to IBRX or ONC?

Which has higher earnings and valuation, IBRX or ONC?

Which has more volatility & risk, IBRX or ONC?

Summary

How does ImmunityBio compare to BioNTech?

Which has preferable valuation and earnings, BNTX or IBRX?

Which has more volatility & risk, BNTX or IBRX?

Do analysts rate BNTX or IBRX?

Is BNTX or IBRX more profitable?

Does the media favor BNTX or IBRX?

Do insiders & institutionals hold more shares of BNTX or IBRX?

Summary

How does ImmunityBio compare to Roivant Sciences?

Which has more volatility and risk, ROIV or IBRX?

Which has stronger earnings and valuation, ROIV or IBRX?

Do insiders & institutionals believe in ROIV or IBRX?

Is ROIV or IBRX more profitable?

Do analysts recommend ROIV or IBRX?

Does the media favor ROIV or IBRX?

Summary

How does ImmunityBio compare to Insmed?

Is IBRX or INSM more profitable?

Do analysts rate IBRX or INSM?

Does the media refer more to IBRX or INSM?

Which has more volatility and risk, IBRX or INSM?

Which has preferable earnings & valuation, IBRX or INSM?

Do insiders and institutionals hold more shares of IBRX or INSM?

Summary

How does ImmunityBio compare to Viatris?

Does the media refer more to IBRX or VTRS?

Do institutionals & insiders believe in IBRX or VTRS?

Which has stronger earnings and valuation, IBRX or VTRS?

Which has more volatility and risk, IBRX or VTRS?

Is IBRX or VTRS more profitable?

Do analysts rate IBRX or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX vs. The Competition

ImmunityBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools